What is the appropriate intravenous artesunate dose for a 53‑kg man?

Intravenous Artesunate Dosing for a 53-kg Man

For a 53-kg man with severe malaria, administer 127.2 mg (2.4 mg/kg × 53 kg) of intravenous artesunate immediately at 0 hours, followed by the same dose at 12 hours, 24 hours, and then once daily until the patient can tolerate oral medication and parasitemia falls below 1%. 1

Dosing Protocol

Initial Three Doses

• First dose (0 hours): 2.4 mg/kg = 127.2 mg IV 1
• Second dose (12 hours): 2.4 mg/kg = 127.2 mg IV 1
• Third dose (24 hours): 2.4 mg/kg = 127.2 mg IV 1

Subsequent Daily Dosing

• Continue 127.2 mg IV once daily after the first 24 hours until all stopping criteria are met 1
• Do not stop before completing at least three doses, even if clinical improvement is apparent 1

Administration Considerations

Timing and Urgency

• The first dose must be given immediately upon diagnosis as severe malaria is a medical emergency; any delay for transfer or additional testing is prohibited 1
• Administer as an IV bolus over several minutes 2

Alternative if Artesunate Unavailable

• If IV artesunate is unavailable, use IV quinine dihydrochloride: 20 mg salt/kg loading dose over 4 hours, followed by 10 mg/kg over 4 hours starting 8 hours after initiation, then every 8 hours 1
• However, artesunate provides faster parasite clearance and shorter ICU stays compared to quinine 1

Stopping Criteria and Transition to Oral Therapy

When to Discontinue IV Artesunate

Discontinue IV artesunate only when ALL of the following criteria are met: 1

• Patient is hemodynamically stable
• Patient is conscious and able to tolerate oral intake
• Peripheral parasitemia has fallen to <1% of red blood cells

Oral Follow-Up Treatment

• Immediately after stopping IV artesunate, begin a full 3-day course of oral artemisinin-based combination therapy (ACT) 1
• Preferred options: artemether-lumefantrine or dihydroartemisinin-piperaquine 1
• The oral ACT course must be given for the complete three days regardless of how many IV artesunate days were administered 1

Monitoring Requirements

Parasitemia Monitoring

• Check peripheral blood smears every 12 hours until parasitemia declines to <1% 1
• Once <1% is reached, check every 24 hours until negative 1
• An initial increase in parasite density within the first 24 hours does not indicate treatment failure 1

Laboratory Monitoring

• Monitor complete blood count, liver function tests, renal function tests, and serum lactate daily to detect organ dysfunction 1
• Check glycemia, plasma bicarbonate, and lactate levels regularly 1

Post-Treatment Surveillance

• Screen for post-artesunate delayed hemolysis (PADH) by checking hemoglobin, haptoglobin, and lactate dehydrogenase on days 7,14,21, and 28 after completing IV artesunate 1
• PADH occurs in approximately 10-15% of patients treated with IV artesunate 1

Common Pitfalls to Avoid

• Do not stop IV artesunate after only three doses if the patient cannot yet tolerate oral intake; continue once-daily IV dosing until oral tolerance is achieved 1
• Do not switch to oral ACT while parasitemia remains ≥1%, as adequate parasite clearance has not been achieved 1
• Do not shorten the oral ACT regimen; a complete three-day course is mandatory after IV artesunate cessation 1
• Do not delay PADH monitoring; this complication can arise up to four weeks post-treatment and requires systematic surveillance 1
• Do not underdose based on concerns about toxicity; the 2.4 mg/kg dose has been shown to be safe and effective in large studies 3